(Bloomberg) — Carlos Ghosn, the former auto-industry titan living as a fugitive in Lebanon, will help start a business program at a university in his troubled native country.

The course will include an executive management program, training in new technologies and an initiative to support startups, Ghosn, 66, said at a press conference Tuesday at Holy Spirit University of Kaslik, known as USEK.



a group of people standing in front of a mirror posing for the camera: Former Nissan CEO Carlos Ghosn Speaks at USEK News Conference


© Bloomberg
Former Nissan CEO Carlos Ghosn Speaks at USEK News Conference

Carlos Ghosn speaks to journalists following a news conference at the Holy Spirit University of Kaslik in Jounieh, Lebanon, on Sept. 29.

Photographer: Hasan Shaaban/Bloomberg

Ghosn, admired in Lebanon for his business successes, declined to answer questions about his dramatic escape from Tokyo to Beirut nine months ago or his own legal situation. He said he’s eager to help the country, which is mired in debt and rudderless after a government collapse, but has

Read More

Brainsway (NASDAQ:BWAY) appears deeply undervalued, given its strong unit sales, clear path to profitability, and large addressable market. Although Brainsway is not currently the market leader, they have arguably superior technology to competitors and are focused on obtaining clearance to treat a wider range of conditions. As revenue recovers from the impact of COVID-19 lockdowns, the company’s share price could appreciate significantly, particularly with potential catalysts like insurance reimbursement approval for the treatment of Obsessive Compulsive Disorder (OCD) and Food and Drug Administration (FDA) clearance for smoking cessation.

Transcranial magnetic stimulation (TMS) is primarily used as a second line treatment for patients with Major Depressive Disorder (MDD) who repeatedly fail to respond or incur intolerable side effects during other treatments. MDD has a massive societal burden with an estimated economic impact in the U.S. of $210 billion per year. The current first line treatment for MDD is pharmacotherapy/psychotherapy and is

Read More